CEL-SCI Receives Government Approval in Bosnia and Herzegovina to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer

07-01-2014 Business Wire HealthComments (0)

BosniaEastern EuropePharmaceuticalUSA

CEL-SCI Receives Government Approval in Bosnia and Herzegovina to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer

Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation (NYSE MKT:CVM) announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Bosnia and

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top